-
Most Popular
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
Pfizer Spares Patients From Erectile Dysfunction Embarrassment
Pfizer has created an industry first by selling its successful Viagra pill directly to consumers -- a move that has implications for major drugmakers and pharmacies alike.
Viagra About to Be Available Online
Drugmaker Pfizer is taking Viagra online and selling it directly to patients on its own website.
Ride This Biotech’s Powerful Bull Trend
Illumina jumped to a 20-month high and is under heavy accumulation.
Take the Money and Run in This Biotech
Following two FDA rejections and two sell signals, it's time to cash out of Gilead Sciences.
3 Pharma Stocks to Buy Into Earnings
We'll learn a lot about healthcare names over the course of this earnings season -- I'm expecting big things from these three drugmakers.
Acadia Booms, But Has a Long Way to Go
ACADIA Pharmaceuticals rocketed to 64% gains yesterday on good news regarding its Parkinson's disease treatment ... but let's not put the cart before the horse.
Bulls vs. Bears: Can Biogen Keep Booming?
Biogen has been soaring on news of its recent drug approval, but the question remains when it can keep it up. Here are the bullish and bearish arguments.
Acquire This Biotech Takeover Target ASAP
Life Technologies is rumored to be looking for a buyer, and the stock is poised for a breakout.
India Drops Patent Bomb on Novartis
India's ruling on a Novartis patent draws a clear line of favor between generic drug companies and Big Pharma.
FDA Approves Novel Type 2 Diabetes Drug
A new treatment for type 2 diabetes has been approved by the Food and Drug Administration.
Biotech Movers: Acadia Jumps, Affymax Crashes
Last week, Acadia Pharmaceuticals rode the winds of good clinical results, while news of mass layoffs sent Affymax crashing again.
The Early Investor Bird Does Catch the Worm
When I look for investment opportunities, I am drawn to some of the world's most innovative companies and these 5 biotech stocks fit the bill for investment
Make a Straightforward Play in Biotech
The iShares Nasdaq Biotechology Index Fund is a great way to get into biotechs ... just not now. It's due for a buyers' exhaustion break, so wait and keep watch.
Pounce on This Biotech Favorite If it Falls Back Into Buying Range
Celgene Corp. (NASDAQ:CELG) broke from a rectangle consolidation, forming a steep bull channel.
FDA Intensifies Warning on Common ‘Z-Pak’ Antibiotic
The Food and Drug Administration is requiring tougher language in the warning labels for azithromycin, an antibiotic, after a study showed an elevelated risk.
Biotech Movers: Peregrine, PharmAthene Climb on Analyst Coverage
Last week in biotech news, Peregrine and PharmAthene both climbed on bullish analyst coverage. Also, find out why Sequenom shed double-digits in one day.
Newborn Cured of HIV
A little girl in Mississippi, who was born infected with HIV, was apparently cured of the disease after receiving a three drug cocktail shortly after birth.
Biotech Movers: Affymax Crashes on Recall
Last week, shares of Affymax got hammered when the company pulled back units of its sole commercial drug. Plus, find out what sent the biggest gainers skyward.
